{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-305187","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2023-12-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.240148+00:00","generated_at":"2026-06-07T06:13:43.712773+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Alaunos Therapeutics terminates CEO Kevin S. Boyle; separation payment ~$331,990 plus consulting deal","bullets":["CEO Kevin S. Boyle terminated effective Dec 22, 2023; separation payment ~$331,990 (six months base salary + COBRA).","Mr. Boyle also executed a mutual release and resigned from board of directors.","Consulting agreement from Jan 1, 2024, for six months at $15,000/month for strategic advisory.","No successor or interim CEO announced; transition details limited."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-305187","json":"https://secwatch.observer/filing/0001193125-23-305187.json","markdown":"https://secwatch.observer/filing/0001193125-23-305187.md","text":"https://secwatch.observer/filing/0001193125-23-305187.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523305187/0001193125-23-305187-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523305187/d473634d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T06:13:43.712773+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13d28ae1f8","claim":"Kevin S. Boyle, Sr. resigned as Director at Alaunos Therapeutics, Inc..","evidence_excerpt":"Pursuant to the terms of his employment agreement, upon his termination Mr. Boyle was deemed to automatically resign from the Company’s board of directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523305187/0001193125-23-305187-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9b0d424508","claim":"Kevin S. Boyle, Sr. was terminated as Chief Executive Officer at Alaunos Therapeutics, Inc..","evidence_excerpt":"On December 22, 2023, Alaunos Therapeutics, Inc. (the “Company”) entered into a Separation and Release Agreement, effective December 22, 2023, with Kevin S. Boyle, Sr. (the “Separation Agreement”), the Company’s Chief Executive Officer, in connection with Mr. Boyle’s termination.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1107421/000119312523305187/0001193125-23-305187-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}